Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $59.4 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 94.19% to $59.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Dec 2025, up 94.19% year-over-year, with the annual reading at $59.4 million for FY2025, 105.23% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $59.4 million at Telix Pharmaceuticals, up from $30.6 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $59.4 million in Q4 2025, with the low at $13.3 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $34.4 million, with a median of $30.6 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax surged 129.56% in 2024, then surged 94.19% in 2025.
  • Over 3 years, Long-Term Deferred Tax stood at $13.3 million in 2023, then skyrocketed by 129.56% to $30.6 million in 2024, then soared by 94.19% to $59.4 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $59.4 million, $30.6 million, and $13.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.